Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

Trial Profile

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Bortezomib; Daratumumab; Ixazomib; Lenalidomide; Levofloxacin
  • Indications Pneumococcal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2019 Planned End Date changed from 1 Nov 2019 to 31 Dec 2019.
    • 19 Oct 2019 Planned primary completion date changed from 1 Aug 2019 to 31 Dec 2019.
    • 17 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top